BRPI0409877A - agentes preventivos ou remédios para doenças hepáticas - Google Patents
agentes preventivos ou remédios para doenças hepáticasInfo
- Publication number
- BRPI0409877A BRPI0409877A BRPI0409877-3A BRPI0409877A BRPI0409877A BR PI0409877 A BRPI0409877 A BR PI0409877A BR PI0409877 A BRPI0409877 A BR PI0409877A BR PI0409877 A BRPI0409877 A BR PI0409877A
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- hepatopathy
- preventive
- hepatic
- therapeutic agent
- Prior art date
Links
- 208000019423 liver disease Diseases 0.000 title abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 230000003449 preventive effect Effects 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000000393 Ghrelin Receptors Human genes 0.000 abstract 1
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 1
- 238000012752 Hepatectomy Methods 0.000 abstract 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 abstract 1
- 206010019663 Hepatic failure Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229910001424 calcium ion Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003028 elevating effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"AGENTES PREVENTIVOS OU REMéDIOS PARA DOENçAS HEPáTICAS". A presente invenção refere-se a um agente preventivo ou terapêutico para doenças hepáticas, compreendendo como ingrediente efetivo um derivado de polipeptídeo, o qual apresenta uma atividade de ligação ao Receptor do Secretagogo do Hormónio do Crescimento (GHS-R), elevando, dessa forma, a concentração intracelular do íon de cálcio, e compreendendo uma seqüência de aminoácidos selecionada do grupo que consiste das seqüências de aminoácidos representadas pelas SEQ ID NOS: 1 a 22, ou uma seqüência de aminoácidos derivada de tal seqüência de aminoácidos mediante remoção, substituição ou adição de um a diversos aminoácidos, diferentes dos resíduos de aminoácidos nas posições 1 a 4 no lado do terminal amino, ou um sal farmacologicamente aceitável do mesmo. O agente preventivo ou terapêutico para doenças hepáticas em conformidade com a presente invenção é de utilidade como uma adequada droga para o tratamento ou prevenção de doenças hepáticas, tais como, hepatite, cirrose hepática e insuficiência hepática. Além disso, o agente preventivo ou terapêutico para doenças hepáticas em conformidade com a presente invenção é também de utilidade como um agente de promoção da regeneração hepática e recuperação da função hepática após uma operação de hepatectomia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003126088 | 2003-04-30 | ||
| PCT/JP2004/006365 WO2004096260A1 (ja) | 2003-04-30 | 2004-04-30 | 肝障害予防治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409877A true BRPI0409877A (pt) | 2006-05-16 |
Family
ID=33410283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409877-3A BRPI0409877A (pt) | 2003-04-30 | 2004-04-30 | agentes preventivos ou remédios para doenças hepáticas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10653637B2 (pt) |
| EP (1) | EP1632244B1 (pt) |
| JP (1) | JP4467518B2 (pt) |
| KR (1) | KR20060015555A (pt) |
| CN (1) | CN1780635B (pt) |
| AT (1) | ATE550029T1 (pt) |
| AU (1) | AU2004233705C1 (pt) |
| BR (1) | BRPI0409877A (pt) |
| CA (1) | CA2523576A1 (pt) |
| ES (1) | ES2383685T3 (pt) |
| WO (1) | WO2004096260A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2566703A1 (en) * | 2004-05-11 | 2005-11-24 | Vishwa Deep Dixit | Methods of inhibiting proinflammatory cytokine expression using ghrelin |
| EP1828243A2 (en) * | 2004-11-30 | 2007-09-05 | Gastrotech Pharma A/S | Growth hormone secretagogue receptor 1a ligands |
| CU23592A1 (es) * | 2006-02-28 | 2010-11-11 | Ct Ingenieria Genetica Biotech | Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 |
| JP2013506686A (ja) | 2009-09-30 | 2013-02-28 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492891A (en) * | 1991-09-05 | 1996-02-20 | Novo Nordisk A/S | Method for treatment of patients with chronic liver disease |
| ES2288151T3 (es) | 1999-07-23 | 2008-01-01 | Kenji Kangawa | Nuevos peptidos. |
| US20030096411A1 (en) * | 1999-12-07 | 2003-05-22 | George Michalopoulos | Novel long-term three-dimensional tissue culture system |
| WO2001056592A1 (en) * | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
| US20010020012A1 (en) * | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| US6967237B2 (en) * | 2000-05-30 | 2005-11-22 | Merck & Co., Inc. | Ghrelin analogs |
| WO2002060472A1 (fr) * | 2001-01-31 | 2002-08-08 | Chugai Seiyaku Kabushiki Kaisha | Remedes pour des etats d'hyponutrition |
-
2004
- 2004-04-30 BR BRPI0409877-3A patent/BRPI0409877A/pt not_active Application Discontinuation
- 2004-04-30 KR KR1020057020591A patent/KR20060015555A/ko not_active Abandoned
- 2004-04-30 ES ES04730725T patent/ES2383685T3/es not_active Expired - Lifetime
- 2004-04-30 WO PCT/JP2004/006365 patent/WO2004096260A1/ja not_active Ceased
- 2004-04-30 JP JP2005505958A patent/JP4467518B2/ja not_active Expired - Lifetime
- 2004-04-30 CA CA002523576A patent/CA2523576A1/en not_active Abandoned
- 2004-04-30 AT AT04730725T patent/ATE550029T1/de active
- 2004-04-30 CN CN2004800116229A patent/CN1780635B/zh not_active Expired - Fee Related
- 2004-04-30 US US10/554,875 patent/US10653637B2/en active Active
- 2004-04-30 EP EP04730725A patent/EP1632244B1/en not_active Expired - Lifetime
- 2004-04-30 AU AU2004233705A patent/AU2004233705C1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1632244A4 (en) | 2009-11-11 |
| JPWO2004096260A1 (ja) | 2006-07-13 |
| CN1780635B (zh) | 2011-04-13 |
| AU2004233705A1 (en) | 2004-11-11 |
| EP1632244A1 (en) | 2006-03-08 |
| EP1632244B1 (en) | 2012-03-21 |
| JP4467518B2 (ja) | 2010-05-26 |
| AU2004233705C1 (en) | 2010-04-01 |
| US20070219114A1 (en) | 2007-09-20 |
| ES2383685T3 (es) | 2012-06-25 |
| WO2004096260A1 (ja) | 2004-11-11 |
| CA2523576A1 (en) | 2004-11-11 |
| KR20060015555A (ko) | 2006-02-17 |
| ATE550029T1 (de) | 2012-04-15 |
| US10653637B2 (en) | 2020-05-19 |
| AU2004233705B2 (en) | 2009-09-17 |
| CN1780635A (zh) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4224111B2 (ja) | 骨粗鬆症の治療のための副甲状腺ホルモン類似体 | |
| CN107001439B (zh) | Gip激动剂化合物及方法 | |
| KR102476550B1 (ko) | 선택적인 pyy 화합물 및 그것의 사용 | |
| KR102653376B1 (ko) | 신경펩티드 y 수용체의 조절제로서의 사이클릭 펩티드 티로신 티로신 화합물 | |
| AU2007330617B2 (en) | Truncated PTH peptides with a cyclic conformation | |
| JP2005511503A5 (ja) | 過剰体重を防止または治療するためのオキシントモジュリン | |
| TW201605467A (zh) | 選擇性ｐｙｙ化合物及其用途 | |
| SK4042002A3 (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
| AU2002339843B2 (en) | Conformationally constrained parathyroid hormone (PTH) analogs | |
| WO2004067021A1 (en) | Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges | |
| JP2006506942A5 (pt) | ||
| WO2004093902A1 (en) | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS | |
| JP5744844B2 (ja) | 副甲状腺ホルモン（ｐｔｈ）受容体アゴニストとしての短鎖ペプチド | |
| US20180009849A1 (en) | Ghrelin analogues | |
| JP2002532067A5 (pt) | ||
| SK12097A3 (en) | Parathormone derivatives and parathormone correlated peptide, preparation method thereof and pharmaceutical composition containing them | |
| DE60326723D1 (de) | Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose | |
| BRPI0409877A (pt) | agentes preventivos ou remédios para doenças hepáticas | |
| JP2007537980A (ja) | 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ | |
| CZ91497A3 (en) | Peptides and pharmaceutical preparations containing thereof | |
| EP4648849A1 (en) | Nmu receptor 2 agonists | |
| AR035942A1 (es) | Antagonistas de somatostatina, un metodo in vitro de enlace de uno o mas receptores de somatostatina, uso de dichos antagonistas para la preparacion de medicamentos y un metodo in vitro para produccion de imagenes de celulas que tienen dichos receptores. | |
| JPWO2020120983A5 (pt) | ||
| RU2003102629A (ru) | Фармацевтический компонент на основе паратиреоидного гормона человека и содержащая его фармацевтическая композиция для интраназального применения | |
| JP2008533101A (ja) | 肥満の治療において使用するための化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 020120089868/RJ DE 24/09/2012. |